TORONTO, Jan. 21, 2013 (GLOBE NEWSWIRE) -- Gemoscan Canada, Inc. ("Gemoscan" or the "Corporation") – (TSX-V:GES) is pleased to announce, in compliance with TSX Venture Exchange ("TSXV") policies, the first tranche closing of its previously disclosed non-brokered private placement for gross proceeds of Cdn.$133,625.00 (the "Offering"). Under the Offering, the Corporation issued 1,069,000 units (the "Units") at Cdn.$0.125 per Unit. Each Unit consisted of one Class A share ("Common Share") and one half of one Class A share purchase warrant (the "Warrants"). Each whole Warrant will entitle the holder to purchase one Common Share of the Corporation (the "Warrant Share") at a price of Cdn.$0.20 per Warrant Share until January 18, 2015. The Units issued will be subject to a statutory four month plus one day hold period from January 18, 2013.
The Corporation paid finder's fees of Cdn.$10,690 and issued 85,520 finder's warrants ("Finder's Warrants") in connection with the Offering. Each Finder's Warrant entitles the holder to purchase one Common Share of the Corporation (the "Finder's Warrant Share") at a price of Cdn.$0.20 per Finder's Warrant Share, until January 18, 2015. The Finder's Warrant Shares issued will be subject to a statutory four month plus one day hold period from January 18, 2013.
The Offering was conducted in reliance upon certain prospectus and registration exemptions. The net proceeds from the Offering will be used to enhance the Corporation's cash on hand and strengthen its working capital position. Post closing, Gemoscan has a total of 28,328,063 Common Shares outstanding.
The Offering and finder's fees are subject to applicable regulatory approvals, including final acceptance of the TSXV.
ABOUT GEMOSCAN CANADA, INC.
Gemoscan is an industry leader in food intolerance management and maintains a first-to-market position with Canada wide distribution through select retail partners. Founded in 2003, using its proprietary patented technology; Gemoscan develops, owns and markets comprehensive food sensitivity and dietary management solutions for consumers, including the HEMOCODETM Food Intolerance System, a personalized naturopathic nutritional program that promotes well-being. Gemoscan is the first and only provider to commercialize a food intolerance management solution directly to consumers in partnership with retailers, and today offers the most comprehensive services available.
Gemoscan Canada, Inc. trades its shares on the Toronto Venture Exchange (TSX-V) under the symbol GES and is quoted on the Munich, Frankfurt and Stuttgart Stock Exchanges under the symbol 1GE.
Forward-Looking Information
This news release contains certain "forward-looking information." All statements, other than statements of historical fact that address activities, events or developments that Gemoscan believes, expects or anticipates will or may occur in the future. These forward-looking statements reflect the current expectations or beliefs of Gemoscan based on information currently available to Gemoscan. Forward-looking statements are subject to a number of significant risks and uncertainties and other factors that may cause the actual results of Gemoscan to differ materially from those discussed in the forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on Gemoscan. Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, Gemoscan disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Although Gemoscan believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to the inherent uncertainty therein.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.